Abstract
Approximately 75% of the UK population has received only one dose of a 2-dose COVID-19 vaccine regime in the face of circulating SARS-CoV-2 Variants of Concern (VOCs). We aimed to determine the levels of vaccine-induced neutralising antibodies to SARS-CoV-2 variants B.1.1.7, B.1.351 and P.1. To do so, we undertook a single-centre cross-sectional study of health care workers (HCWs) and outpatients with immunodeficiencies (IDP) based at the same critical care tertiary NHS Trust, following a single dose of either BNT162b2 or AZD1222 vaccines. Data revealed low neutralising antibodies (nAbs) in IDPs, with only 5% and 3% showing detectable neutralisation of B.1.1.7 and B.1.351, respectively. In contrast, healthy HCWs without a prior SARS-CoV-2 infection demonstrated a wide range of nAb titres post-vaccination with responses significantly lower than HCWs with prior SARS-CoV-2 infection. Neutralisation of VOCs with the E484K mutation (B.1.351 and P.1) were consistently lower in HCWs in the absence of evidence of prior SARS-CoV-2 infection (p<0.001). Notably, in vaccinated HCWs with prior SARS-CoV-2 infection, there was a significant increase of neutralising titres post-vaccination to all variants, compared to their pre-vaccination neutralisation titres. This underscores the importance of vaccination to boost neutralising antibody breadth to VOCs, and also provides support for the hypothesis that repeated immunisations will boost protective immunity in individuals without prior SARS-CoV-2 exposure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the RPH Trust and the clinical studies team, HCWs and Outpatients who participated in this study. We also thank members of the HICC consortium. We acknowledge support from Project OVEL (BBSRC, UKRI), the NIHR/UKRI grant, COV0170 Humoral immune Correlates from COVID-19 (HICC) based at the Lab of Viral Zoonotics, University of Cambridge, the Royal Papworth Hospital NHS Trust, and EU FETopen Grant Virofight, (RW, SE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approved by Research Ethics Committee Wales, IRAS: 9619412/WA/0148. Amendment 5
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors declare no competing interests. We thank the RPH Trust and clinical studies team, HCWs and Outpatients who participated in this study. We also thank members of the HICC consortium. We acknowledge support from the NIHR/UKRI grant, COV0170 Humoral immune Correlates from COVID-19 (HICC) based at the Lab of Viral Zoonotics, University of Cambridge, the Royal Papworth Hospital NHS Trust and EU FETopen Grant Virofight, (RW, SE).
Data Availability
All raw data will be made available upon request to corresponding author.
